SpaceX IPO: Retail Investors to Play Historic Role in Record-Breaking Public Offering 
Anthropic Fights Pentagon Blacklisting in Dual Federal Court Battles 
Samsung Electronics Eyes Record Q1 Profit Amid AI-Driven Chip Boom 
Pony.ai, Uber, and Verne Launch Europe's First Commercial Robotaxi Service in Zagreb 
Britain Courts Anthropic Amid US Defense Department Dispute 
Kia Cuts EV Sales Target for 2030 Amid Slowing Demand and U.S. Policy Shifts 
UPS and Teamsters Reach Agreement to Limit Driver Severance Program 
Ford Issues Major Recall on Over 422,000 Vehicles Due to Windshield Wiper Defect 
Pershing Square Bids €30.40 Per Share to Acquire Universal Music Group in $9.4B Deal 
Alibaba Shares Slide as Jefferies Slashes Price Target Over AI Spending and Business Losses 
Disney Plans to Cut 1,000 Jobs Amid Ongoing Restructuring Efforts 
Private Credit Under Pressure: Is a Slow-Motion Crisis Unfolding? 
FedEx Pilots and Union Reach Tentative Agreement on 40% Pay Increase 
Paramount Skydance Secures $24B from Gulf Sovereign Wealth Funds for Warner Bros. Discovery Takeover 
Chalco Stock Surges as Q1 2025 Profit Forecast Jumps Up to 58% 
NORCROSS, Ga., Oct. 17, 2016 -- Immucor, Inc., a global leader in transfusion and transplantation diagnostics, today announced that it will hold a conference call with debt investors on Friday, October 21, 2016 at 11:00 a.m. ET to discuss its fiscal 2017 first quarter results.
Interested debt investors and analysts should contact Immucor Investor Relations at [email protected] or 770-441-2051 for details.
About Immucor
Founded in 1982, Immucor is a global leader in transfusion and transplantation diagnostics that facilitate patient-donor compatibility. Our mission is to ensure that patients in need of blood, organs or stem cells get the right match that is safe, accessible and affordable. With the right match, we can transform a life together. For more information on Immucor, please visit our website at www.immucor.com.
CONTACT: Michele Howard 770-441-2051
